BridgeBio Stock Up 60% So Far In Dec., IPO Lockup Period Expires Today

• Shares of BridgeBio Pharma have gone up 60% so far in December, as the clinical-stage biopharmaceutical company focused on developing medicines for genetic diseases gears up for some important events in the months ahead, reported Markets Insider.

• BridgeBio's most advanced pipeline product is fosdenopterin, also known as BBP-870, for the treatment of molybdenum cofactor deficiency type A, for which the company initiated a rolling US submission early in December.

• BP-265, also known as AG10, is in the ongoing Phase III ATTRibute-CM trial for transthyretin amyloidosis cardiomyopathy, while the Phase III ATTRibute-PN study of the drug in transthyretin amyloidosis with polyneuropathy is on track to begin in the first quarter of 2020.

• Meanwhile, a late-stage trial of patidegib, also known as BBP-009, in patients with Gorlin syndrome is also underway, with top-line data expected in 2021.

• A pivotal study of BBP-831, also known as infigratinib, in second-line cholangiocarcinoma is ongoing, with data expected in 2020. It is also in preclinical development for the treatment of achondroplasia.

• Finally, a Phase I/II study of BBP-589 for recessive dystrophic epidermolysis bullosa is underway, with topline data anticipated during 2020.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.